CYDX (Cyduct Diagnostics) Total Current Liabilities: $0.00 Mil (As of . 20)


What is Cyduct Diagnostics Total Current Liabilities?

Cyduct Diagnostics CYDX -17.78% Total Current Liabilities is $0.00 Mil as of . 20.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Cyduct Diagnostics's total current liabilities for the quarter that ended in . 20 was $0.00

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Cyduct Diagnostics Total Current Liabilities Related Terms

Cyduct Diagnostics Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for Cyduct Diagnostics's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cyduct Diagnostics Total Current Liabilities Chart

Cyduct Diagnostics Annual Data
Trend
Total Current Liabilities

Cyduct Diagnostics Quarterly Data
Total Current Liabilities

Cyduct Diagnostics Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Cyduct Diagnostics's Total Current Liabilities for the fiscal year that ended in . 20 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=+
+Other Current Liabilities+Current Deferred Liabilities
=+
=0.00

Cyduct Diagnostics's Total Current Liabilities for the quarter that ended in . 20 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=+
+Other Current Liabilities+Current Deferred Liabilities
=+
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of $0.00 Mil mean?
Cyduct Diagnostics (CYDX) has a Total Current Liabilities of $0.00 Mil as of . 20. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Cyduct Diagnostics and its competitors.
Is Cyduct Diagnostics' Total Current Liabilities too high?
Cyduct Diagnostics' current Total Current Liabilities is $0.00 Mil.
How does Cyduct Diagnostics' Total Current Liabilities compare to SECI and QTXB?
Cyduct Diagnostics' Total Current Liabilities of $0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Medical Devices & Instruments company?
A good Total Current Liabilities depends on the Medical Devices & Instruments industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Cyduct Diagnostics and its competitors. Cyduct Diagnostics's current Total Current Liabilities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cyduct Diagnostics stock overvalued right now?
Cyduct Diagnostics (CYDX) has a current Total Current Liabilities of $0.00 Mil. The current Total Current Liabilities is $0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For Cyduct Diagnostics (CYDX), the current Total Current Liabilities is $0.00 Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cyduct Diagnostics Business Description

Address 1698 Post Road East, Suite 1A, Westport, CT, USA, 06880
Cyduct Diagnostics Inc is a clinical-stage diagnostic company. It focuses on creating and enhancing a portfolio of technologies and assets based on the early assessment and detection of Breast Cancer. Its technology platform of MammoView devices is a single-use, high-margin product that assesses, screens, detects, monitors, and facilitates the treatment of identifiable changes that distinguish variations in breast health. The company markets these products under its Solos Endoscopy brand, along with a line of branded surgical instruments, manufactured by third parties to its design specifications, mainly endoscopes and hand-held surgical instruments for the minimally invasive surgery market.